Addendum
Cabozantinib (renal cell carcinoma) - Addendum to Commission A21-49
Report documents
-
Addendum
Cabozantinib (renal cell carcinoma) - Addendum to Commission A21-49
Additional information
Federal Joint Committee (G-BA)
2021-10-21 A G-BA decision was published.
Project details
- Project no.
- G21-27
- Commission
- Commission awarded on 08.09.2021 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Health Economics
- Topic
- Kidneys and urinary system
- Note
-
If, in the course of the discussions on a commission of the GBA, a need for further revision arises, IQWiG submits an addendum. The GBA decides on the number of patients in the SHI target population.
Connected Projects
-
Dossier assessment
Cabozantinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed